Coherus Oncology (CHRS) Depreciation & Amortization (CF) (2013 - 2026)

Coherus Oncology has disclosed Depreciation & Amortization (CF) across 14 years of filings, most recently posting $881000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $881000.0, down 15.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.8 million (down 21.93% YoY), and the FY2025 annual result was $3.9 million, down 25.63% from the prior year.
• Depreciation & Amortization (CF) came in at $881000.0 for Q1 2026 at Coherus Oncology, down from $896000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.5 million in Q3 2024 to a low of $767000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $966000.0 (2025), against an average of $1.0 million.
• Across the five-year window, Depreciation & Amortization (CF) soared 72.3% in 2024 and slumped 37.64% in 2025, its largest moves.
• Coherus Oncology's Depreciation & Amortization (CF) stood at $1.0 million in 2022, then rose by 1.24% to $1.1 million in 2023, then decreased by 2.82% to $1.0 million in 2024, then declined by 13.26% to $896000.0 in 2025, then declined by 1.67% to $881000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $881000.0 (Q1 2026), $896000.0 (Q4 2025), and $966000.0 (Q3 2025), per Business Quant data.